Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) reported positive topline results from its Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia, with the study meeting its FDA-agreed primary endpoint and all secondary endpoints.
Avexitide produced a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events versus placebo through Week 16, with a p-value of 0.000003. Amylyx now plans to submit a New Drug Application to the FDA by the end of 2026 and is preparing for a potential commercial launch in 2027 if approved.
Key Investor Takeaways
- Amylyx Pharmaceuticals (NASDAQ:AMLX) said the Phase 3 LUCIDITY trial met its FDA-agreed primary endpoint with a 55% reduction in Level 2 and Level 3 hypoglycemic events.
- The 78-participant study also met all secondary endpoints, covering Level 2 events measured by SMBG and CGM as well as independently adjudicated Level 3 events.
- Avexitide was generally well tolerated, with no serious adverse events related to treatment during the double-blind period.
- Amylyx plans an avexitide NDA submission by year-end, creating a defined near-term regulatory catalyst.
- There are currently no FDA-approved therapies for post-bariatric hypoglycemia, according to the company, while avexitide already holds FDA Breakthrough Therapy and Orphan Drug designations.
Why AMLX Stock Is in Focus
The Phase 3 LUCIDITY results move avexitide closer to a potential regulatory filing after the trial achieved both its primary endpoint and every secondary efficacy endpoint.
The multicentre study enrolled 78 adults with post-bariatric hypoglycemia following Roux-en-Y gastric bypass surgery. Participants were randomised 3:2 to receive either 90 mg of avexitide subcutaneously once daily or placebo.
Beyond the 55% reduction on the primary composite endpoint, Amylyx reported consistent, highly statistically significant and clinically meaningful reductions in Level 2 hypoglycemic events measured through self-monitoring of blood glucose and continuous glucose monitoring, as well as independently adjudicated Level 3 events.
Safety results also supported the regulatory pathway. Most adverse events were mild to moderate, with diarrhea, injection-site erythema and injection-site bruising the most common. No serious adverse events were attributed to avexitide, and neither treatment group experienced changes in body weight during the 16-week double-blind period.
Why This Matters for Investors
The LUCIDITY readout reduces an important element of clinical uncertainty around avexitide by demonstrating efficacy against an FDA-agreed Phase 3 primary endpoint while also producing supportive secondary and safety results.
That matters because Amylyx is now moving toward an NDA rather than another pivotal efficacy study. The company said submission preparations are already underway and expects to file with the FDA before the end of the year.
The potential commercial positioning is also notable. Amylyx estimates PBH affects approximately 8% of U.S. patients who have undergone the two most common bariatric procedures, representing around 160,000 people. The company said there are currently no FDA-approved treatments for the condition.
Avexitide’s existing Breakthrough Therapy Designation for PBH could also be relevant as the program enters the regulatory stage, although the designation does not guarantee approval.
For investors, the focus now shifts from whether the pivotal study can demonstrate efficacy toward regulatory execution, the FDA’s assessment of the complete data package and Amylyx’s ability to prepare for commercialization.
What to Watch Next
Amylyx’s planned NDA submission by the end of 2026 is the most immediate catalyst. The company also intends to present detailed LUCIDITY data at an upcoming medical meeting, which should provide additional information beyond the topline results.
The 32-week LUCIDITY open-label extension remains underway, while Amylyx continues an expanded access program launched in May.
Beyond the filing itself, investors can watch for the FDA’s acceptance of the NDA, subsequent regulatory timelines and further information around Amylyx’s preparations for a potential 2027 avexitide launch if the treatment receives approval.
Amylyx Pharmaceuticals stock price
